Originally Posted by Conductor71
So we have a paucity of PWP for clinical trials...ha! I am applying for NIH GDNF trials and apparently I have a lot of company, but there are only 28 openings. Looks like maybe we are just more selective.
Anyway does anyone know what happens when more people qualify for a trial than there are open slots? Do they try to balance the trial so being a woman might be an advantage but being youngest may hurt chances? Anyone know or have experience with this?
No experience but will hazard a guess that they will favor picking PWP that increase the odds of a successful outcome. We've all read the stories of how drug companies "cherry pick" those patients most likely to make their experimental drug/protocol/procedure a success.
Case in point: we were invited to participate in a trial. Excellent health sans PD, young onset, very proactive in terms of exercise, etc. I would think this is particularly important if the trial involves any kind of surgery. Who wouldn't want to stack the deck with the "healthiest" PWP?
To be fair, I get that if a lot of participants have had PD for decades, this could make the results harder to read, and increase the risks of adverse events, but the reality is that most PWP have had it for a very long time. So trying to just pick young onsetters, or those who are newly dx'd, etc., does not really represent the PD population.
These are just my thoughts, as I said, no personal experience.